Evidence map›Paper›PMID 37426666›Full record

ArticleFrontiers in immunology2023

Citrullination of C1-inhibitor as a mechanism of impaired complement regulation in rheumatoid arthritis.

Myriam Martin, Sara C Nilsson, David Eikrem, Karin Fromell, Carsten Scavenius, Leonie M Vogt, Ewa Bielecka, Jan Potempa, Jan J Enghild, Bo Nilsson and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Complement 3 and 4 impact in osteoarthritis.Biomarkers in medicine · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 4 countries.

Myriam MartinDepartment of Translational Medicine, Division of Medical Protein Chemistry, Lund University, Malmö, Sweden.
Sara C NilssonDepartment of Translational Medicine, Division of Medical Protein Chemistry, Lund University, Malmö, Sweden.
David EikremDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.
Karin FromellDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.
Carsten ScaveniusDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Leonie M VogtDepartment of Translational Medicine, Division of Medical Protein Chemistry, Lund University, Malmö, Sweden.
Ewa BieleckaMalopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland.
Jan PotempaDepartment of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.
Jan J EnghildDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Bo NilssonDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.
Kristina N EkdahlDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.
Meliha C KapetanovicDepartment of Clinical Sciences Lund, Rheumatology, Lund University, Skåne University Hospital, Lund, Sweden.
Anna M BlomDepartment of Translational Medicine, Division of Medical Protein Chemistry, Lund University, Malmö, Sweden.
Lund University · SEUppsala University · SEAarhus University · DKJagiellonian University · PLLinnaeus University · SEUniversity of Louisville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dysregulated complement activation, increased protein citrullination, and production of autoantibodies against citrullinated proteins are hallmarks of rheumatoid arthritis (RA). Citrullination is induced by immune cell-derived peptidyl-Arg deiminases (PADs), which are overactivated in the inflamed synovium. We characterized the effect of PAD2- and PAD4-induced citrullination on the ability of the plasma-derived serpin C1-inhibitor (C1-INH) to inhibit complement and contact system activation. Methods: Citrullination of the C1-INH was confirmed by ELISA and Western blotting using a biotinylated phenylglyoxal probe. C1-INH-mediated inhibition of complement activation was analyzed by C1-esterase activity assay. Downstream inhibition of complement was studied by C4b deposition on heat-aggregated IgGs by ELISA, using pooled normal human serum as a complement source. Inhibition of the contact system was investigated by chromogenic activity assays for factor XIIa, plasma kallikrein, and factor XIa. In addition, autoantibody reactivity to native and citrullinated C1-INH was measured by ELISA in 101 RA patient samples. Results: C1-INH was efficiently citrullinated by PAD2 and PAD4. Citrullinated C1-INH was not able to bind the serine protease C1s and inhibit its activity. Citrullination of the C1-INH abrogated its ability to dissociate the C1-complex and thus inhibit complement activation. Consequently, citrullinated C1-INH had a decreased capacity to inhibit C4b deposition Conclusion: Citrullination of the C1-INH by recombinant human PAD2 and PAD4 enzymes impaired its ability to inhibit the complement and contact systems

Indexed as

Arthritis, RheumatoidCitrullinationAutoantibodiesFactor XIaFactor XIIaHumansPlasma KallikreinProtein-Arginine DeiminasesProteinsAutoantibodiesFactor XIaFactor XIIaPlasma KallikreinProtein-Arginine DeiminasesProteinsACPAC1-inhibitorcitrullinationcomplement systemPADrheumatoid arthritissynovial fluid

Identifiers

PMID37426666
PMCPMC10326043
OpenAlexW4381998575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.